Enzo Biochem Shares Outstanding 2010-2023 | ENZ

Enzo Biochem shares outstanding from 2010 to 2023. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Enzo Biochem Annual Shares Outstanding
(Millions of Shares)
2022 49
2021 48
2020 48
2019 47
2018 47
2017 46
2016 47
2015 45
2014 43
2013 40
2012 39
2011 38
2010 38
2009 38
Enzo Biochem Quarterly Shares Outstanding
(Millions of Shares)
2023-01-31 49
2022-10-31 49
2022-07-31 49
2022-04-30 49
2022-01-31 48
2021-10-31 48
2021-07-31 48
2021-04-30 49
2021-01-31 48
2020-10-31 48
2020-07-31 48
2020-04-30 48
2020-01-31 48
2019-10-31 48
2019-07-31 47
2019-04-30 48
2019-01-31 47
2018-10-31 47
2018-07-31 47
2018-04-30 47
2018-01-31 47
2017-10-31 47
2017-07-31 46
2017-04-30 46
2017-01-31 46
2016-10-31 46
2016-07-31 47
2016-04-30 46
2016-01-31 47
2015-10-31 46
2015-07-31 45
2015-04-30 46
2015-01-31 45
2014-10-31 45
2014-07-31 43
2014-04-30 43
2014-01-31 42
2013-10-31 41
2013-07-31 40
2013-04-30 40
2013-01-31 39
2012-10-31 39
2012-07-31 39
2012-04-30 39
2012-01-31 39
2011-10-31 39
2011-07-31 38
2011-04-30 38
2011-01-31 38
2010-10-31 38
2010-07-31 38
2010-04-30 38
2010-01-31 38
2009-10-31 38
2009-07-31 38
2009-04-30 37
2009-01-31 37
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.106B $0.107B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.194B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00